In the past decade, nucleic acid therapies have seen a boon in development and clinical
translation largely due to advances in nanotechnology that have enabled their safe and …

Recent years have seen a marked increase in research on chimeric antigen receptor T
(CAR-T) cells, with specific relevance to the treatment of hematological malignancies. Here …

Chimeric antigen receptor (CAR) T cell therapy has implemented impressive advances in
the treatment of B-cell lymphoma. However, the complex production process of CAR T cells …

While existing synthetic technologies for ex vivo T-cell activation face challenges like
suboptimal expansion rates and low effectiveness, artificial antigen-presenting cells …

The intersection of immunology and nanotechnology has provided significant advancements
in biomedical research and clinical applications over the years. Immunology aims to …

Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of
haematological malignancies by achieving impressive remission rates in patients with highly …

Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating
hematological cancers but faces significant challenges in solid-tumor treatment and overall …

Lipid nanoparticles and polymeric nanoparticles are promising biomaterial platforms for
robust intracellular DNA and mRNA delivery, highlighted by the widespread use of …

Originally devised for cancer control, mRNA vaccines have risen to the forefront of medicine
as effective instruments for control of infectious disease, notably their pivotal role in …

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a revolutionary approach
in the treatment of malignancies. Despite its remarkable successes, this field continues to …